• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Local Immune Modulation and Vector Selection Dictate Gene Therapy Efficacy for Dent Disease

by
November 7, 2026
in Health
Reading Time: 6 mins read
0
Local Immune Modulation and Vector Selection Dictate Gene Therapy Efficacy for Dent Disease

Local Immune Modulation and Vector Selection Dictate Gene Therapy Efficacy for Dent Disease

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Dent disease type 1 is an inherited, X-linked kidney disorder that impairs proximal tubular endocytosis, yet experimental gene replacement strategies face substantial biological hurdles regarding vector durability, host immune responses, and organ development. In a preclinical investigation published in Gene Therapy, researchers led by Baisong Lu and Anthony Atala at Wake Forest University Health Sciences evaluated viral gene transfer in a ClC-5-deficient mouse model, demonstrating that co-administering biodegradable rapamycin-releasing microspheres enabled lentiviral vectors to maintain therapeutic protein clearance for up to ten months in adult kidneys. In contrast, non-integrating adeno-associated virus serotype 9 vectors achieved only temporary or undetectable reductions in urinary disease markers across developmental stages, establishing that persistent transgene expression within renal tissue does not automatically guarantee functional phenotypic correction.

Because CLCN5 resides on the X chromosome, the condition primarily affects male patients, although female carriers can exhibit clinical manifestations. To systematically resolve unresolved questions surrounding vector persistence, immune elimination, and recipient maturity, the research team compared integrating lentiviral vectors against episomal adeno-associated viral vectors across neonatal and mature experimental cohorts.

Prior investigations in ClC-5-null mice revealed that direct renal delivery of lentiviral vectors encoding human CLCN5 cDNA produced long-term phenotypic recovery when administered to newborn mice, whereas mature adult recipients experienced therapeutic benefits that waned after three to four months. The researchers hypothesized that host immune responses targeting the foreign human transgene product accelerated this decline in adult animals with mature immune systems. To counteract this barrier without inducing the widespread complications of systemic immunosuppression, the investigators formulated biodegradable polymeric microspheres composed of poly(L-lactide) and poly(L-lactide)-co-poly(ethylene glycol). These microspheres, prepared via an oil-in-water emulsion method and verified by high-performance liquid chromatography, were engineered to release rapamycin locally within the renal architecture over extended periods.

Adult ClC-5-mutant mice, aged two to three months, underwent bilateral retrograde ureteral microinjections delivering lentiviral vectors carrying codon-optimized human CLCN5 driven by the human elongation factor 1-alpha promoter, administered either alone or alongside 4.5 micrograms of encapsulated rapamycin per kidney. Quantitative biochemical assessments of twenty-four-hour urine collections demonstrated that while both treated groups exhibited substantial drops in urinary beta-2 microglobulin at one month, animals receiving vector alone experienced diminishing therapeutic responses by four months and returned to untreated baseline levels by eight months. In stark contrast, animals receiving the local rapamycin co-treatment maintained significant reductions in urinary beta-2 microglobulin excretion throughout four and ten months post-delivery, showing that localized immunosuppressive delivery prevented the premature therapeutic loss observed in control animals.

Molecular and histological analyses confirmed that local rapamycin administration preserved therapeutic efficacy by protecting transgene protein abundance rather than altering initial vector entry or transcription. Semiquantitative polymerase chain reaction targeting codon-optimized human CLCN5 vector DNA alongside the reference gene Dmd demonstrated comparable genomic presence between groups, and reverse transcription polymerase chain reaction normalized against mouse Ppib confirmed steady transgene transcription regardless of drug co-delivery. However, immunoblotting and densitometric analyses revealed significantly higher ClC-5 protein levels in renal tissue from the rapamycin-supplemented cohort. This selective preservation of translated protein indicates that localized mechanistic target of rapamycin inhibition suppressed immune-mediated clearance of the human ClC-5 antiporter, although direct cellular effects on tubular biology cannot be completely excluded.

Despite the therapeutic durability of integrating lentiviral vectors, translational hurdles such as the risk of insertional mutagenesis and vector dissemination to germline tissues prompted the authors to rigorously assess recombinant adeno-associated virus serotype 9, an episomal platform with established regulatory approvals for clinical gene therapy. The team constructed an optimized AAV shuttle plasmid containing the identical EF1-alpha promoter and human CLCN5 cDNA, removing the post-transcriptional regulatory element to comply with viral packaging constraints. To determine whether administering this non-integrating vector during early postnatal life could bypass adult immune reactivity, researchers performed percutaneous intrarenal injections of ten billion vector genomes per kidney into male mutant pups on postnatal day one.

Neonatal AAV9 administration generated notable early functional improvements, with western blot and enzyme-linked immunosorbent assays showing marked reductions in both urinary beta-2 microglobulin and vitamin D-binding protein at one month post-treatment. Nevertheless, this therapeutic benefit proved transient. Longitudinal monitoring revealed progressive elevations in urinary marker excretion at two, three, and four months. By four months, urinary vitamin D-binding protein concentrations in all four treated mutants approached levels seen in untreated controls, and beta-2 microglobulin returned to baseline concentrations in half of the cohort. Furthermore, urinary albumin excretion remained unchanged even during peak therapeutic activity at one month, suggesting distinct physiological handling mechanisms for different urinary protein species.

Crucially, the loss of functional efficacy in neonatally treated mice occurred despite the clear long-term persistence of functional vector DNA, transcribed messenger RNA, and translated ClC-5 protein. Polymerase chain reaction detected vector DNA in three of four animals, reverse transcriptase-dependent amplification confirmed human CLCN5 cDNA across all four treated mutants, and western blots confirmed robust ClC-5 expression at four months. Immunofluorescence co-staining with segment-specific markers—including Lotus tetragonolobus lectin for proximal tubules, peanut agglutinin for distal segments and medullary thick ascending limbs, and aquaporin-2 for collecting duct intercalated cells—demonstrated appropriate localization of ClC-5 to apical tubular membranes. However, spatial mapping revealed that while ClC-5 was distributed broadly across the cortex and corticomedullary junction at three weeks, expression at four months was largely confined to deep corticomedullary regions, with marked depletion in superficial proximal convolutions.

The study attributes this spatial redistribution and loss of efficacy to the rapid cellular dynamics of the developing rodent kidney, where proximal tubules undergo more than a sixfold elongation between postnatal day twenty-one and two months due to intense epithelial proliferation. Because recombinant adeno-associated viral genomes exist predominantly as non-integrating episomes, extensive cell division appears to dilute vector genomes within rapidly expanding superficial nephron segments. As a result, persistent transgene expression was largely restricted to non-dividing tubular cells situated deeper within the medulla, which do not serve as the primary functional sites for bulk low-molecular-weight protein endocytosis, thereby severing the link between global transgene retention and whole-organ physiological recovery.

To assess whether mature quiescent tissue could overcome proliferative genome dilution, the investigators injected one hundred billion adeno-associated viral genomes into the ureters of adult mutant mice, with and without rapamycin microspheres. Although vector genomes and transcripts were consistently detected, and ClC-5 protein remained readily demonstrable eight to ten months post-injection, the intervention failed to achieve functional correction. Urinary beta-2 microglobulin and vitamin D-binding protein excretion showed no measurable reduction at one or four months in either experimental arm, and beta-2 microglobulin levels even trended upward four months after treatment. Although rapamycin microsphere co-delivery produced a trend toward increased ClC-5 protein density, this molecular elevation did not translate into functional tubular reabsorption.

The authors discussed several potential biological explanations for the failure of adult AAV9 delivery, noting that serotype 9 capsids may inefficiently transduce the exact proximal tubular subpopulation responsible for receptor-mediated endocytosis, or that continuous baseline epithelial turnover in adult kidneys gradually destabilizes episomal loads below therapeutic thresholds. Furthermore, dissimilarities between marker proteins were evident throughout the investigation; lentiviral therapy selectively reduced beta-2 microglobulin while leaving vitamin D-binding protein largely unaffected. The researchers noted that while beta-2 microglobulin binds directly to the endocytic receptor megalin, vitamin D-binding protein relies on cubilin docking prior to megalin-mediated internalization, indicating that restoring complex multi-receptor endocytosis requires higher spatial precision and transduction density.

Several methodological limitations contextualize these findings, including the fact that systemic and intrarenal rapamycin concentrations and release kinetics were not directly quantified following retrograde ureteral injection. The authors highlighted that fluid flow through the urinary tract could potentially displace polymeric microspheres, altering drug retention compared to subcapsular delivery routes. Additionally, metabolic side effects such as rapamycin-induced glucose intolerance were not evaluated, though the authors noted that the single low dose administered is unlikely to carry substantial risk. The investigators also acknowledged that hypercalciuria was not consistently reversed, likely reflecting milder baseline phenotypes in the outbred mouse colonies. Ultimately, the comparative study demonstrates that successful renal gene therapy for Dent disease type 1 demands not merely long-lived vector expression, but precise vector tropism and localized immune modulation tailored to the dynamic cellular architecture of the nephron.

Subject of Research: Comparative evaluation of lentiviral and adeno-associated viral CLCN5 gene therapy combined with localized rapamycin immune modulation in a mouse model of Dent disease type 1

Article Title: Renal CLCN5 gene therapy for Dent disease type 1: local rapamycin immune modulation and age-dependent outcomes with lentiviral and AAV9 vectors

Article References: Lyu, P., Bostanci, A., Jiang, C., Yoo, K. W., Broadhurst, R., Atala, A., & Lu, B. (2026). Renal CLCN5 gene therapy for Dent disease type 1: local rapamycin immune modulation and age-dependent outcomes with lentiviral and AAV9 vectors. Gene Therapy. https://doi.org/10.1038/s41434-026-00655-9

Image Credits: AI Generated

DOI: 10.1038/s41434-026-00655-9

Keywords: Dent disease type 1, CLCN5, gene therapy, lentiviral vectors, adeno-associated virus, rapamycin microspheres, proximal tubule, proteinuria, renal tubulopathy, endocytosis, Renal, gene

News Source: Juliet Wilcox. (November 7, 2026). Local Immune Modulation and Vector Selection Dictate Gene Therapy Efficacy for Dent Disease. Scienmag.

Tags: adeno-associated virusCLCN5Dent disease type 1endocytosisgeneGene Therapylentiviral vectorsProteinuriaproximal tubulerapamycin microspheresrenalrenal tubulopathy
Share12Tweet7Share2ShareShareShare1

Related Posts

Case Report Describes Suspected Great Auricular Nerve Injury After Jugular Vein Catheterization

Case Report Describes Suspected Great Auricular Nerve Injury After Jugular Vein Catheterization

November 18, 2026
HIV Medication Packaging Transition Improves Patient Satisfaction and Management Practices

HIV Medication Packaging Transition Improves Patient Satisfaction and Management Practices

November 18, 2026

Nearly 98 Percent of Willing Joint Replacement Patients Completed Same-Day Discharge

November 18, 2026

RSM01 Demonstrates High Barrier to Respiratory Syncytial Virus Resistance in Laboratory Tests

November 18, 2026

POPULAR NEWS

  • Survey Reveals Lack of Parental Awareness Regarding Sibling Visitation Policies in PICUs

    Survey Reveals Lack of Parental Awareness Regarding Sibling Visitation Policies in PICUs

    29 shares
    Share 12 Tweet 7
  • Review Details How Circulating Tumor Cells Survive Bloodstream Stresses to Drive Metastasis

    29 shares
    Share 12 Tweet 7
  • Laparoscopic Colectomy Cuts Surgical Site Infection Risk in Obese Adults

    29 shares
    Share 12 Tweet 7
  • Aging-Related Immune Cell Imbalances Linked to Subclinical Coronary Artery Disease

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Case Report Describes Suspected Great Auricular Nerve Injury After Jugular Vein Catheterization

HIV Medication Packaging Transition Improves Patient Satisfaction and Management Practices

Nearly 98 Percent of Willing Joint Replacement Patients Completed Same-Day Discharge

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.